패밀리 비교 | StructureMoa

보내기

PCSK9 inhibitor chemical & modality series

PCSK9 / LDL-C

화합물 9
관계 28
SMILES 9/9

Drug: 5
Derivative: 3
Scaffold: 1

Oral macrocyclic peptide PCSK9i (enlicitide / Lipfendra) mapped with injectable mAb (evolocumab, alirocumab) and siRNA (inclisiran) class peers for LDL-C lowering.

맵 열기 →

GLP-1 / incretin agonist series

GLP-1 / incretin

화합물 10
관계 51
SMILES 10/10

Drug: 8
Derivative: 1
Scaffold: 1

GLP-1 receptor agonist chemotypes from exenatide/liraglutide to semaglutide, dual GIP/GLP-1 tirzepatide, triple agonists, and oral small-molecule orforglipron.

맵 열기 →

패밀리 간 overlap

pcsk9-inhibitors ↔ glp1-agonists · 평균 유사도(상위 쌍): 0.51

Core-compound Morgan similarity

Morgan fingerprint, radius 2, 2048 bits, Tanimoto. This value does not predict potency, biological activity, safety, or clinical efficacy.

	PCSK9 inhibitor chemical & modality series	GLP-1 / incretin agonist series
PCSK9 inhibitor chemical & modality series	1.00	0.15
GLP-1 / incretin agonist series	0.15	1.00